Zacks: Analysts Expect Transenterix Inc (NYSE:TRXC) Will Post Earnings of -$0.11 Per Share

Equities analysts expect that Transenterix Inc (NYSE:TRXC) will report earnings of ($0.11) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Transenterix’s earnings, with estimates ranging from ($0.11) to ($0.10). Transenterix also reported earnings per share of ($0.11) during the same quarter last year. The business is scheduled to announce its next earnings results after the market closes on Wednesday, August 2nd.

According to Zacks, analysts expect that Transenterix will report full year earnings of ($0.42) per share for the current year, with EPS estimates ranging from ($0.45) to ($0.37). For the next fiscal year, analysts forecast that the company will report earnings of ($0.33) per share, with EPS estimates ranging from ($0.42) to ($0.29). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Transenterix.

Transenterix (TRXC) traded up 3.867% during mid-day trading on Monday, reaching $0.779. The company’s stock had a trading volume of 2,693,416 shares. Transenterix has a 52-week low of $0.45 and a 52-week high of $2.33. The firm has a 50 day moving average price of $0.56 and a 200 day moving average price of $1.07. The company’s market cap is $115.70 million.

WARNING: “Zacks: Analysts Expect Transenterix Inc (NYSE:TRXC) Will Post Earnings of -$0.11 Per Share” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/08/10/zacks-analysts-expect-transenterix-inc-nysetrxc-will-post-earnings-of-0-11-per-share-updated-updated-updated.html.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Get a free copy of the Zacks research report on Transenterix (TRXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply